How Stelara Targets Crohn's Inflammation
Stelara (ustekinumab) treats moderate to severe Crohn's disease by blocking two key signaling proteins, interleukin-12 (IL-12) and interleukin-23 (IL-23). These cytokines drive the immune system's overactive response in Crohn's, leading to chronic gut inflammation, ulcers, and tissue damage. By binding to their shared p40 subunit, Stelara stops these signals, reducing T-cell activation and cytokine production that perpetuate the disease.[1][2]
Patients typically start with one intravenous infusion (around 520 mg based on weight) to quickly suppress inflammation, followed by subcutaneous injections every 8 weeks.[3]
Why IL-12 and IL-23 Matter in Crohn's
In Crohn's, genetic factors and gut bacteria trigger excessive IL-12/IL-23 production by antigen-presenting cells. This promotes Th1 and Th17 immune cells, which release pro-inflammatory TNF-alpha and other mediators, causing bowel wall thickening and fistulas. Stelara's targeted blockade interrupts this cycle without broadly suppressing the immune system like older drugs.[1][4]
Clinical trials (e.g., UNITI-1 and UNITI-2) showed 50-60% of patients achieving clinical remission at week 8 post-infusion, with endoscopic improvement in 30-40%—better than placebo.[5]
How Stelara Compares to Other Crohn's Biologics
Unlike TNF inhibitors like Humira (adalimumab) or Inflectra (infliximab biosimilar), which target broader inflammation and fail in 30-40% of patients due to non-response or antibodies, Stelara works downstream via the IL-23 pathway. It's effective for TNF-failures: about 40% respond after prior anti-TNF use.[3][5]
| Drug | Target | Crohn's Approval | Common Use After Failure Of |
|------|--------|------------------|-----------------------------|
| Stelara | IL-12/IL-23 p40 | 2016 | Anti-TNFs |
| Humira | TNF-alpha | 2007 | N/A (first-line biologic) |
| Skyrizi | IL-23 p19 | 2022 | Anti-TNFs |
| Entyvio | Gut integrin | 2014 | Anti-TNFs |
Stelara has fewer infections than steroids but similar risks to other biologics (e.g., 3-5% serious infections).[3]
Starting Treatment and What to Expect Long-Term
Initial response often appears within 6 weeks, with maintenance dosing preventing relapse—over 70% maintain remission at year 1 in responders.[5] It's not curative; stopping usually leads to flare-ups. Real-world data show sustained remission in 50-60% at 3 years.[6]
Common Side Effects and Patient Risks
Most tolerate it well (upper respiratory infections in 20-30%), but watch for serious issues: infections (TB screening required), rare malignancies, or hypersensitivity. No increased bowel perforation risk vs. placebo. Pregnancy data is limited—use Category B labeling.[3][7]
When Does Stelara's Patent Expire for Crohn's?
Core patents on ustekinumab expire in 2023-2025 in the US/EU, but formulation and method-of-use patents extend exclusivity to 2025-2032, with biosimilars like Wezlana approved in 2023 for other indications but delayed for Crohn's due to litigation.[8] Check DrugPatentWatch.com for latest expiry details and challengers.
Sources
[1] Stelara prescribing information, Janssen 2023. https://www.stelara.com/
[2] Sands et al., NEJM 2012 (Crohn's mechanism review).
[3] FDA label, ustekinumab. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/761044lbl.pdf
[4] Neurath, Nat Rev Immunol 2014 (IL-23 in IBD).
[5] Feagan et al., NEJM 2016 (UNITI trials).
[6] Engelke et al., Aliment Pharmacol Ther 2022 (real-world).
[7] Stelara HCP site adverse events.
[8] DrugPatentWatch.com, Stelara patents. https://www.drugpatentwatch.com/p/tradename/STELARA